- Home
- RCUS vs DCOM Comparison
RCUS vs DCOM Comparison
Compare RCUS & DCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- DCOM
- Stock Information
- Founded
- RCUS 2015
- DCOM 1864
- Country
- RCUS United States
- DCOM United States
- Employees
- RCUS N/A
- DCOM N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- DCOM Major Banks
- Sector
- RCUS Health Care
- DCOM Finance
- Exchange
- RCUS Nasdaq
- DCOM Nasdaq
- Market Cap
- RCUS 1.4B
- DCOM 1.2B
- IPO Year
- RCUS 2018
- DCOM 1996
- Fundamental
- Price
- RCUS $14.71
- DCOM $36.32
- Analyst Decision
- RCUS Buy
- DCOM Buy
- Analyst Count
- RCUS 12
- DCOM 6
- Target Price
- RCUS $34.50
- DCOM $31.17
- AVG Volume (30 Days)
- RCUS 767.1K
- DCOM 363.1K
- Earning Date
- RCUS 11-06-2024
- DCOM 10-22-2024
- Dividend Yield
- RCUS N/A
- DCOM 2.75%
- EPS Growth
- RCUS N/A
- DCOM N/A
- EPS
- RCUS N/A
- DCOM 1.50
- Revenue
- RCUS $263,000,000.00
- DCOM $313,737,000.00
- Revenue This Year
- RCUS $112.97
- DCOM N/A
- Revenue Next Year
- RCUS N/A
- DCOM $23.85
- P/E Ratio
- RCUS N/A
- DCOM $24.21
- Revenue Growth
- RCUS 119.17
- DCOM N/A
- 52 Week Low
- RCUS $13.50
- DCOM $17.29
- 52 Week High
- RCUS $20.31
- DCOM $36.50
- Technical
- Relative Strength Index (RSI)
- RCUS 40.35
- DCOM 69.98
- Support Level
- RCUS $14.15
- DCOM $33.92
- Resistance Level
- RCUS $15.01
- DCOM $36.05
- Average True Range (ATR)
- RCUS 1.00
- DCOM 1.33
- MACD
- RCUS -0.20
- DCOM 0.16
- Stochastic Oscillator
- RCUS 11.49
- DCOM 97.45
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities.